SCHEMBL3018625

SCHEMBL3018625

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
USP2 O75604 1/20 0.52
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PKM P14618 2/20 0.50
LMNA P02545 2/20 0.49
MAPK1 P28482 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TSHR P16473 2/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
GBA1 P04062 1/20 0.46
KDM4E B2RXH2 1/20 0.46
APAF1 O14727 1/20 0.46
TP53 P04637 1/20 0.45
HDAC3 O15379 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012775 0.95 MEN1 (0.51) ALDH1A1SMN1; SMN2L3MBTL1USP2PKM
SCHEMBL3023130 0.92 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2L3MBTL1USP2MAPT
SCHEMBL3001539 0.91 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2L3MBTL1USP2MAPT
SCHEMBL3015421 0.91 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2L3MBTL1USP2MAPT
SCHEMBL3000163 0.91 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1USP2PKM
SCHEMBL3011971 0.90 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1USP2MAPT
SCHEMBL2998702 0.90 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1USP2PKM
SCHEMBL3018793 0.90 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2L3MBTL1USP2MAPT
SCHEMBL3015956 0.90 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1USP2PKM
SCHEMBL3010733 0.90 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.